A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 Diabetes

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 10 Jun 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Aldesleukin (Primary) ; Antithymocyte globulin (Primary) ; Etanercept (Primary) ; Exenatide (Primary) ; Pegfilgrastim (Primary)
Indications Type 1 diabetes mellitus
Focus Pharmacodynamics
Acronyms DIPIT

04 Jun 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
16 May 2024 Planned End Date changed from 1 Dec 2028 to 1 Dec 2029.
16 May 2024 Planned primary completion date changed from 1 Dec 2027 to 1 Dec 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com